Surgify Medical, an Espoo-based MedTech company focused on improving the safety and precision of bone surgery with its Surgify Halo technology, has successfully raised €7 million in Series A funding.
The funding round was led by ZEISS Ventures, the corporate venture arm of the Carl Zeiss Group, with participation from the European Innovation Council Fund (EIC Fund). Surgify’s existing investors, including Lednil and Cascara Ventures, also participated in the financing.
“ZEISS brings unparalleled experience in surgical technology and a global network, while the EIC’s continued support and earlier grant financing underscore the European innovation ecosystem’s confidence in our solution,” said Visa Sippola, Co-founder and CEO of Surgify Medical. “With this funding and regulatory approvals in both the EU and the U.S., we are well-positioned to bring our unique technology to more surgeons and patients internationally.”
Founded in 2017, Surgify Medical is dedicated to innovating bone surgery by making it safer, faster, and more precise. The company’s flagship product, Surgify Halo, is designed to differentiate between hard and soft tissues, reportedly providing enhanced protection against incidental soft tissue damage and streamlining procedures.
The benefits of Surgify Halo extend beyond its core market of head, neck, and spine surgeries. Surgify’s technology also has the potential to impact the growing field of robotic surgery by enabling reliable automated bone resection.
With the investment, the company plans to take the next steps toward becoming a leading supplier in the multi-billion-euro market for bone surgery devices. Building on a successful Nordic market launch, the company will expand its operations in the EU and the United States, where Surgify says key hospitals have already started adopting the technology.
“Surgify’s technology is a major breakthrough in today’s evolving healthcare landscape. With over a thousand patient procedures, Surgify Halo has already left a significant footprint in the field. The company aims to protect patients, save costs, and has already achieved groundbreaking developments in robotic surgery applications,” said Alan Raffensperger, Chairman of Surgify Medical.
According to the company, conventional surgical drills spin tens of thousands of times per minute and can be dangerous if they come into contact with critical soft tissue. At worst, such soft tissue damage can result in severe injury to the patient. Soft tissue injuries are considered a highly relevant surgical complication in many types of head, neck, and spine procedures involving bone resection and result in over €4 billion in annual complication-related costs globally.
Surgify Halo reportedly cuts bone while providing unique protective capabilities against incidental injuries to soft tissues such as central nervous system structures, blood vessels, and nerves. The technology is said to provide effective bone resection in combination with a soft tissue protection feature for enhanced safety and precision in surgical procedures.
“We are excited to partner with Surgify in their mission to establish a new benchmark for surgical safety. Surgify’s Halo burrs offer exceptional control at cutting rates comparable to traditional burrs, while simultaneously safeguarding delicate soft tissues. This makes the switch to Halo burrs an obvious choice for surgeons,” explains Dr Boris Hofmann, Head of ZEISS Ventures. “We are eager to support the team as they expand their solution on a global scale.”
To date, Surgify Medical has raised €14 million in total funding and has offices in Finland, Sweden, Denmark and the United States.
Read the orginal article: https://www.eu-startups.com/2025/05/finnish-medtech-startup-surgify-medical-raises-e7-million-to-make-bone-surgery-safer-with-tissue-selective-technology/
